Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression

Cell Reports

Volumn 3, Issue 1, 2013, Pages 52-59

  Yang, Chunzhang ^a   Huntoon, Kristin ^a   Ksendzovsky, Alexander ^a   Zhuang, Zhengping ^a   Lonser, Russell R ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LB 205; MESSENGER RNA; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MISSENSE MUTATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA TRANSLATION; TUMOR GROWTH; WILD TYPE;

ANIMALS; CELL LINE; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MUTANT PROTEINS; MUTATION, MISSENSE; NEOPLASMS; PROTEIN STABILITY; PROTEOLYSIS; RNA, MESSENGER; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ANIMALIA; RODENTIA;

EID: 84873154699     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.12.007     Document Type: Article

References (40)

1. Ali T., Kandil D., Piperdi B. Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL). Pancreas 2012, 41:492-493.
2. Atuk N.O., Stolle C., Owen J.A., Carpenter J.T., Vance M.L. Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and mutation analysis in a large, multigenerational kindred. J. Clin. Endocrinol. Metab. 1998, 83:117-120.
3. Béroud C., Collod-Béroud G., Boileau C., Soussi T., Junien C. UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. Hum. Mutat. 2000, 15:86-94.
4. Chung J., Roberts A.M., Chow J., Coady-Osberg N., Ohh M. Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway. Oncogene 2006, 25:3079-3083.
5. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 2000, 275:25733-25741.
6. Dollfus H., Massin P., Taupin P., Nemeth C., Amara S., Giraud S., Béroud C., Dureau P., Gaudric A., Landais P., Richard S. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest. Ophthalmol. Vis. Sci. 2002, 43:3067-3074.
7. Feldman D.E., Thulasiraman V., Ferreyra R.G., Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell 1999, 4:1051-1061.
8. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
9. Gallou C., Joly D., Méjean A., Staroz F., Martin N., Tarlet G., Orfanelli M.T., Bouvier R., Droz D., Chrétien Y., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 1999, 13:464-475.
10. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7:85-90.
11. Hansen W.J., Ohh M., Moslehi J., Kondo K., Kaelin W.G., Welch W.J. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 2002, 22:1947-1960.
12. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1995, 1:822-826.
13. Jonasch E., McCutcheon I.E., Waguespack S.G., Wen S., Davis D.W., Smith L.A., Tannir N.M., Gombos D.S., Fuller G.N., Matin S.F. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann. Oncol. 2011, 22:2661-2666.
14. Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
15. Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000, 19:5435-5443.
16. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
17. Li L., Zhang L., Zhang X., Yan Q., Minamishima Y.A., Olumi A.F., Mao M., Bartz S., Kaelin W.G. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol. Cell. Biol. 2007, 27:5381-5392.
18. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Oldfield E.H. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
19. Lu J., Yang C., Chen M., Ye D.Y., Lonser R.R., Brady R.O., Zhuang Z. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. USA 2011, 108:21200-21205.
20. Lubensky I.A., Gnarra J.R., Bertheau P., Walther M.M., Linehan W.M., Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol. 1996, 149:2089-2094.
21. Maher E.R., Kaelin W.G. von Hippel-Lindau disease. Medicine (Baltimore) 1997, 76:381-391.
22. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
23. McClellan A.J., Scott M.D., Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 2005, 121:739-748.
24. Mehta G.U., Shively S.B., Duong H., Tran M.G., Moncrief T.J., Smith J.H., Li J., Edwards N.A., Lonser R.R., Zhuang Z., et al. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. Neoplasia 2008, 10:1146-1153.
25. Melville M.W., McClellan A.J., Meyer A.S., Darveau A., Frydman J. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell. Biol. 2003, 23:3141-3151.
26. Nordstrom-O'Brien M., van der Luijt R.B., van Rooijen E., van den Ouweland A.M., Majoor-Krakauer D.F., Lolkema M.P., van Brussel A., Voest E.E., Giles R.H. Genetic analysis of von Hippel-Lindau disease. Hum. Mutat. 2010, 31:521-537.
27. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000, 2:423-427.
28. Okuda H., Saitoh K., Hirai S., Iwai K., Takaki Y., Baba M., Minato N., Ohno S., Shuin T. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 2001, 276:43611-43617.
29. Ong K.R., Woodward E.R., Killick P., Lim C., Macdonald F., Maher E.R. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum. Mutat. 2007, 28:143-149.
30. Richard S., Gardie B., Couvé S., Gad S. Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin. Cancer Biol. 2012, Published online May 30, 2012.
31. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
32. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W., Collins D., Majoor-Krakauer D., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
33. Shen C., Kaelin W.G. The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 2012, Published online June 13, 2012.
34. Stolle C., Glenn G., Zbar B., Humphrey J.S., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R., Linehan W.M. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 1998, 12:417-423.
35. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19:4298-4309.
36. van der Harst E., de Krijger R.R., Dinjens W.N., Weeks L.E., Bonjer H.J., Bruining H.A., Lamberts S.W., Koper J.W. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int. J. Cancer 1998, 77:337-340.
37. Wanebo J.E., Lonser R.R., Glenn G.M., Oldfield E.H. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J. Neurosurg. 2003, 98:82-94.
38. Wizigmann-Voos S., Breier G., Risau W., Plate K.H. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995, 55:1358-1364.
39. Yang C., Asthagiri A.R., Iyer R.R., Lu J., Xu D.S., Ksendzovsky A., Brady R.O., Zhuang Z., Lonser R.R. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc. Natl. Acad. Sci. USA 2011, 108:4980-4985.
40. Zhuang Z., Bertheau P., Emmert-Buck M.R., Liotta L.A., Gnarra J., Linehan W.M., Lubensky I.A. A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am. J. Pathol. 1995, 146:620-625.